Alan S Perelson

List of Publications by Year
in descending order

501 papers	56,821 citations	1371 108 h-index	1461 220 g-index
522 all docs	522 docs citations	522 times ranked	25413 citing authors

#	Article	IF	Citations
1	Complex decay dynamics of HIV virions, intact and defective proviruses, and 2LTR circles following initiation of antiretroviral therapy. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	46
2	Antithetic effect of interferon-α on cell-free and cell-to-cell HIV-1 infection. PLoS Computational Biology, 2022, 18, e1010053.	3.2	1
3	Disrupting autorepression circuitry generates "open-loop lethality" to yield escape-resistant antiviral agents. Cell, 2022, 185, 2086-2102.e22.	28.9	7
4	HIV influences clustering and intracellular replication of hepatitis C virus. Journal of Viral Hepatitis, 2021, 28, 334-344.	2.0	6
5	Suppression of hepatitis B virus through therapeutic activation of RIG-I and IRF3 signaling in hepatocytes. IScience, 2021, 24, 101969.	4.1	17
6	Zika virus dynamics: Effects of inoculum dose, the innate immune response and viral interference. PLoS Computational Biology, 2021, 17, e1008564.	3.2	10
7	CD8 Lymphocyte Depletion Enhances the Latency Reversal Activity of the SMAC Mimetic AZD5582 in ART-Suppressed Simian Immunodeficiency Virus-Infected Rhesus Macaques. Journal of Virology, 2021, 95, .	3.4	17
8	Mechanistic Modeling of SARS‐CoV‐2 and Other Infectious Diseases and the Effects of Therapeutics. Clinical Pharmacology and Therapeutics, 2021, 109, 829-840.	4.7	70
9	A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2. PLoS Biology, 2021, 19, e3001128.	5.6	99
10	Success of prophylactic antiviral therapy for SARS-CoV-2: Predicted critical efficacies and impact of different drug-specific mechanisms of action. PLoS Computational Biology, 2021, 17, e1008752.	3.2	41
11	Unified model of short- and long-term HIV viral rebound for clinical trial planning. Journal of the Royal Society Interface, 2021, 18, 20201015.	3.4	6
12	Viral Load Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospitalized Individuals With Coronavirus Disease 2019. Open Forum Infectious Diseases, 2021, 8, ofab153.	0.9	20
13	A participant-derived xenograft model of HIV enables long-term evaluation of autologous immunotherapies. Journal of Experimental Medicine, 2021, 218, .	8.5	9
14	Understanding Hepatitis B Virus Dynamics and the Antiviral Effect of Interferon Alpha Treatment in Humanized Chimeric Mice. Journal of Virology, 2021, 95, e0049220.	3.4	14
15	Immunological Correlates of the HIV-1 Replication-Competent Reservoir Size. Clinical Infectious Diseases, 2021, 73, 1528-1531.	5.8	4
16	Mechanistic basis of post-treatment control of SIV after anti-α4β7 antibody therapy. PLoS Computational Biology, 2021, 17, e1009031.	3.2	4
17	Detection of significant antiviral drug effects on COVID-19 with reasonable sample sizes in randomized controlled trials: A modeling study. PLoS Medicine, 2021, 18, e1003660.	8.4	32
18	Modeling HIV-1 Within-Host Dynamics After Passive Infusion of the Broadly Neutralizing Antibody VRC01. Frontiers in Immunology, 2021, 12, 710012.	4.8	6

#	Article	IF	Citations
19	Modeling Within-Host Dynamics of SARS-CoV-2 Infection: A Case Study in Ferrets. Viruses, 2021, 13, 1635.	3.3	24
20	Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. Nature Medicine, 2021, 27, 1718-1724.	30.7	39
21	Modeling hepatitis C virus kinetics during liver transplantation reveals the role of the liver in virus clearance. ELife, 2021, 10, .	6.0	4
22	In vivo kinetics of SARS-CoV-2 infection and its relationship with a person's infectiousness. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	108
23	Disentangling the lifespans of hepatitis C virus–infected cells and intracellular vRNA replication–complexes during direct–acting anti–viral therapy. Journal of Viral Hepatitis, 2020, 27, 261-269.	2.0	3
24	Accumulated mutations by 6 months of infection collectively render transmitted/founder HIV-1 significantly less fit. Journal of Infection, 2020, 80, 210-218.	3.3	5
25	Models of SIV rebound after treatment interruption that involve multiple reactivation events. PLoS Computational Biology, 2020, 16, e1008241.	3.2	3
26	Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 18754-18763.	7.1	53
27	Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of anti–HIV-1 IgG1 antibodies in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 18002-18009.	7.1	44
28	A Coupled Mathematical Model of the Intracellular Replication of Dengue Virus and the Host Cell Immune Response to Infection. Frontiers in Microbiology, 2020, 11, 725.	3.5	28
29	Continuous and discrete modeling of HIV-1 decline on therapy. Journal of Mathematical Biology, 2020, 81, 1-24.	1.9	6
30	Timing of Antiviral Treatment Initiation is Critical to Reduce SARS–CoV–2 Viral Load. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 509-514.	2.5	170
31	A direct-acting antiviral drug abrogates viremia in Zika virus–infected rhesus macaques. Science Translational Medicine, 2020, 12, .	12.4	21
32	Single hepatocytes show persistence and transcriptional inactivity of hepatitis B. JCI Insight, 2020, 5, .	5.0	17
33	Quantification of Ebola virus replication kinetics in vitro. PLoS Computational Biology, 2020, 16, e1008375.	3.2	10
34	Mathematical modeling of hepatitis C RNA replication, exosome secretion and virus release. PLoS Computational Biology, 2020, 16, e1008421.	3.2	7
35	Predictions of time to HIV viral rebound following ART suspension that incorporate personal biomarkers. PLoS Computational Biology, 2019, 15, e1007229.	3.2	30
36	Within-host mathematical models of hepatitis B virus infection: Past, present, and future. Current Opinion in Systems Biology, 2019, 18, 27-35.	2.6	28

#	Article	IF	Citations
37	Regulation of T cell expansion by antigen presentation dynamics. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 5914-5919.	7.1	67
38	Modeling the Effects of Morphine-Altered Virus Specific Antibody Responses on HIV/SIV Dynamics. Scientific Reports, 2019, 9, 5423.	3.3	12
39	Mathematical modelling identifies the role of adaptive immunity as a key controller of respiratory syncytial virus in cotton rats. Journal of the Royal Society Interface, 2019, 16, 20190389.	3.4	19
40	Principles Governing Establishment versus Collapse of HIV-1 Cellular Spread. Cell Host and Microbe, 2019, 26, 748-763.e20.	11.0	30
41	Acute hepatitis B virus infection in humanized chimeric mice has multiphasic viral kinetics. Hepatology, 2018, 68, 473-484.	7.3	30
42	A Pharmacokinetic/Viral Kinetic Model to Evaluate Treatment of Chronic HCV Infection with a Non-Nucleoside Polymerase Inhibitor. Antiviral Therapy, 2018, 23, 353-361.	1.0	3
43	Intracellular Hepatitis C Virus Modeling Predicts Infection Dynamics and Viral Protein Mechanisms. Journal of Virology, 2018, 92, .	3.4	21
44	Probabilistic control of HIV latency and transactivation by the Tat gene circuit. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 12453-12458.	7.1	23
45	Determinants of the efficacy of HIV latency-reversing agents and implications for drug and treatment design. JCI Insight, 2018, 3, .	5.0	14
46	Variation in cell-associated unspliced HIV RNA on antiretroviral therapy is associated with the circadian regulator brain-and-muscle-ARNT-like-1. Aids, 2018, 32, 2119-2128.	2.2	28
47	CD8+ lymphocyte control of SIV infection during antiretroviral therapy. PLoS Pathogens, 2018, 14, e1007350.	4.7	20
48	Early HIV Infection Predictions: Role of Viral Replication Errors. SIAM Journal on Applied Mathematics, 2018, 78, 1863-1890.	1.8	7
49	A New Age-Structured Multiscale Model of the Hepatitis C Virus Life-Cycle During Infection and Therapy With Direct-Acting Antiviral Agents. Frontiers in Microbiology, 2018, 9, 601.	3.5	16
50	Correlation Between Anti-gp41 Antibodies and Virus Infectivity Decay During Primary HIV-1 Infection. Frontiers in Microbiology, 2018, 9, 1326.	3.5	13
51	Superinfection and cure of infected cells as mechanisms for hepatitis C virus adaptation and persistence. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E7139-E7148.	7.1	16
52	Mathematical modeling of within‑host Zika virus dynamics. Immunological Reviews, 2018, 285, 81-96.	6.0	40
53	Introduction to modeling viral infections and immunity. Immunological Reviews, 2018, 285, 5-8.	6.0	22
54	No recovery of replication-competent HIV-1 from human liver macrophages. Journal of Clinical Investigation, 2018, 128, 4501-4509.	8.2	41

#	Article	IF	Citations
55	Population dynamics of host and pathogens. , 2018, , 265-278.		3
56	Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 1922-1927.	7.1	50
57	Zika Virus Persistence in the Central Nervous System and Lymph Nodes of Rhesus Monkeys. Cell, 2017, 169, 610-620.e14.	28.9	191
58	Reply to Padmanabhan and Dixit: Hepatitis C virus entry inhibitors for optimally boosting direct-acting antiviral-based treatments. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E4527-E4529.	7.1	9
59	Prevalence of end of treatment RNA-positive/sustained viral response in HCV patients treated with sofosbuvir combination therapies. Therapeutic Advances in Gastroenterology, 2017, 10, 68-73.	3.2	15
60	The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics?. Scientific Reports, 2017, 7, 10233.	3.3	20
61	How Germinal Centers Evolve Broadly Neutralizing Antibodies: the Breadth of the Follicular Helper T Cell Response. Journal of Virology, 2017, 91, .	3.4	32
62	Zika plasma viral dynamics in nonhuman primates provides insights into early infection and antiviral strategies. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 8847-8852.	7.1	89
63	Modelling the effects of phylogeny and body size on within-host pathogen replication and immune response. Journal of the Royal Society Interface, 2017, 14, 20170479.	3.4	23
64	On the Death Rate of Abortively Infected Cells: Estimation from Simian-Human Immunodeficiency Virus Infection. Journal of Virology, 2017, 91, .	3.4	11
65	The Role of Infected Cell Proliferation in the Clearance of Acute HBV Infection in Humans. Viruses, 2017, 9, 350.	3.3	25
66	Editorial: Transplant Rejection and Tolerance—Advancing the Field through Integration of Computational and Experimental Investigation. Frontiers in Immunology, 2017, 8, 616.	4.8	1
67	A strongly selected mutation in the HIV-1 genome is independent of T cell responses and neutralizing antibodies. Retrovirology, 2017, 14, 46.	2.0	2
68	Nonlatching positive feedback enables robust bimodality by decoupling expression noise from the mean. PLoS Biology, 2017, 15, e2000841.	5.6	19
69	NS5A inhibitors unmask differences in functional replicase complex half-life between different hepatitis C virus strains. PLoS Pathogens, 2017, 13, e1006343.	4.7	12
70	Treatment with integrase inhibitor suggests a new interpretation of HIV RNA decay curves that reveals a subset of cells with slow integration. PLoS Pathogens, 2017, 13, e1006478.	4.7	45
71	Modelling the Interaction between Danoprevir and Mericitabine in the Treatment of Chronic HCV Infection. Antiviral Therapy, 2016, 21, 297-306.	1.0	2
72	Mathematical Modeling. , 2016, , 199-211.		1

#	Article	IF	Citations
73	Molecular clock of HIV-1 envelope genes under early immune selection. Retrovirology, 2016, 13, 38.	2.0	11
74	Hepatitis C virus dynamics and cellular gene expression in <scp>uPA</scp>â€‹<scp>SCID</scp> chimeric mice with humanized livers during intravenous silibinin monotherapy. Journal of Viral Hepatitis, 2016, 23, 708-717.	2.0	14
75	Transmission of Multiple HIV-1 Subtype C Transmitted/founder Viruses into the Same Recipients Was not Determined by Modest Phenotypic Differences. Scientific Reports, 2016, 6, 38130.	3.3	18
76	Estimating biologically relevant parameters under uncertainty for experimental within-host murine West Nile virus infection. Journal of the Royal Society Interface, 2016, 13, 20160130.	3.4	39
77	Modeling Viral Spread. Annual Review of Virology, 2016, 3, 555-572.	6.7	79
78	Zika viral dynamics and shedding in rhesus and cynomolgus macaques. Nature Medicine, 2016, 22, 1448-1455.	30.7	270
79	Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study. The Lancet Gastroenterology and Hepatology, 2016, 1, 97-104.	8.1	80
80	Authors' response: Danoprevir pharmacokinetic/viral kinetic model for treating chronic HCV â€" some considerations. Antiviral Therapy, 2016, 21, 648-649.	1.0	0
81	Viral dynamic modelling of Hepatitis C and resistanceâ€‹associated variants in haemophiliacs. Haemophilia, 2016, 22, 543-548.	2.1	1
82	Single-Genome Sequencing of Hepatitis C Virus in Donor-Recipient Pairs Distinguishes Modes and Models of Virus Transmission and Early Diversification. Journal of Virology, 2016, 90, 152-166.	3.4	17
83	SPMM: estimating infection duration of multivariant HIV-1 infections. Bioinformatics, 2016, 32, 1308-1315.	4.1	13
84	Residual Viremia in Treated HIV+ Individuals. PLoS Computational Biology, 2016, 12, e1004677.	3.2	58
85	Modeling the Effects of Morphine on Simian Immunodeficiency Virus Dynamics. PLoS Computational Biology, 2016, 12, e1005127.	3.2	19
86	Severity of Liver Disease Affects HCV Kinetics in Patients Treated with Intravenous Silibinin Monotherapy. Antiviral Therapy, 2015, 20, 149-155.	1.0	14
87	A Pharmacokinetic/Viral Kinetic Model to Evaluate the Treatment Effectiveness of Danoprevir against Chronic HCV. Antiviral Therapy, 2015, 20, 469-477.	1.0	7
88	Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b). Aids, 2015, 29, 2419-2426.	2.2	18
89	Recombination Enhances HIV-1 Envelope Diversity by Facilitating the Survival of Latent Genomic Fragments in the Plasma Virus Population. PLoS Computational Biology, 2015, 11, e1004625.	3.2	19
90	Modeling the Effects of Vorinostat In Vivo Reveals both Transient and Delayed HIV Transcriptional Activation and Minimal Killing of Latently Infected Cells. PLoS Pathogens, 2015, 11, e1005237.	4.7	46

#	Article	IF	Citations
91	Transmitted Virus Fitness and Host T Cell Responses Collectively Define Divergent Infection Outcomes in Two HIV-1 Recipients. PLoS Pathogens, 2015, 11, e1004565.	4.7	44
92	Modelling hepatitis C therapy—predicting effects of treatment. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 437-445.	17.8	72
93	Post-treatment control of HIV infection. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 5467-5472.	7.1	166
94	Proof-of-Principle for Immune Control of Global HIV-1 Reactivation In Vivo. Clinical Infectious Diseases, 2015, 61, 120-128.	5.8	17
95	Quantification of Hepatitis C Virus Cell-to-Cell Spread Using a Stochastic Modeling Approach. Journal of Virology, 2015, 89, 6551-6561.	3.4	32
96	The challenges of modelling antibody repertoire dynamics in HIV infection. Philosophical Transactions of the Royal Society B: Biological Sciences, 2015, 370, 20140247.	4.0	9
97	Competitive exclusion by autologous antibodies can prevent broad HIV-1 antibodies from arising. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 11654-11659.	7.1	58
98	Reversion and T Cell Escape Mutations Compensate the Fitness Loss of a CD8+ T Cell Escape Mutant in Their Cognate Transmitted/Founder Virus. PLoS ONE, 2014, 9, e102734.	2.5	8
99	Preexisting compensatory amino acids compromise fitness costs of a HIV-1ÂT cell escape mutation. Retrovirology, 2014, 11, 101.	2.0	12
100	Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 2307-2312.	7.1	579
101	Antibody Responses during Hepatitis B Viral Infection. PLoS Computational Biology, 2014, 10, e1003730.	3.2	60
102	A Hepatitis C Virus Infection Model with Time-Varying Drug Effectiveness: Solution and Analysis. PLoS Computational Biology, 2014, 10, e1003769.	3.2	15
103	Inferring Viral Dynamics in Chronically HCV Infected Patients from the Spatial Distribution of Infected Hepatocytes. PLoS Computational Biology, 2014, 10, e1003934.	3.2	45
104	Impact of Different Oseltamivir Regimens on Treating Influenza A Virus Infection and Resistance Emergence: Insights from a Modelling Study. PLoS Computational Biology, 2014, 10, e1003568.	3.2	60
105	Quantifying the Turnover of Transcriptional Subclasses of HIV-1-Infected Cells. PLoS Computational Biology, 2014, 10, e1003871.	3.2	19
106	Effects of Aging on Influenza Virus Infection Dynamics. Journal of Virology, 2014, 88, 4123-4131.	3.4	114
107	Modulation of HCV replication after combination antiretroviral therapy in HCV/HIV co-infected patients. Science Translational Medicine, 2014, 6, 246ra98.	12.4	19
108	Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. Gut, 2014, 63, 161-169.	12.1	51

#	Article	IF	Citations
109	Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients. Hepatology, 2014, 59, 1706-1714.	7.3	23
110	Viral kinetic modeling: state of the art. Journal of Pharmacokinetics and Pharmacodynamics, 2014, 41, 431-443.	1.8	82
111	Treatment of hepatitis C with an interferon-based lead-in phase: a perspective from mathematical modelling. Antiviral Therapy, 2014, 19, 469-477.	1.0	6
112	Analysis of Hepatitis C Viral Kinetics during Administration of Two Nucleotide Analogues: Sofosbuvir (Gs-7977) and Gs-0938. Antiviral Therapy, 2014, 19, 211-220.	1.0	44
113	Modeling the Dynamics and Migratory Pathways of Virus-Specific Antibody-Secreting Cell Populations in Primary Influenza Infection. PLoS ONE, 2014, 9, e104781.	2.5	2
114	Quantifying T lymphocyte turnover. Journal of Theoretical Biology, 2013, 327, 45-87.	1.7	207
115	Human systems immunology: Hypothesis-based modeling and unbiased data-driven approaches. Seminars in Immunology, 2013, 25, 193-200.	5.6	28
116	Use of Laser Capture Microdissection to Map Hepatitis C Virus–Positive Hepatocytes in Human Liver. Gastroenterology, 2013, 145, 1404-1413.e10.	1.3	74
117	Modeling the within-host dynamics of HIV infection. BMC Biology, 2013, 11, 96.	3.8	214
118	Hepatitis C Viral Kinetics. Clinics in Liver Disease, 2013, 17, 13-26.	2.1	25
119	Innate Immune Tolerance and the Role of Kupffer Cells in Differential Responses to Interferon Therapy Among Patients With HCV Genotype 1 Infection. Gastroenterology, 2013, 144, 402-413.e12.	1.3	66
120	Understanding triphasic HCV decline during treatment in the era of IL28B polymorphisms and direct acting antiviral agents via mathematical modeling. Journal of Hepatology, 2013, 58, 840-842.	3.7	4
121	Spatial Aspects of HIV Infection. Lecture Notes on Mathematical Modelling in the Life Sciences, 2013, , 3-31.	0.4	10
122	Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 3991-3996.	7.1	298
123	Towards multiscale modeling of influenza infection. Journal of Theoretical Biology, 2013, 332, 267-290.	1.7	63
124	Modeling sequence evolution in HIV-1 infection with recombination. Journal of Theoretical Biology, 2013, 329, 82-93.	1.7	9
125	Mathematical modeling of escape of HIV from cytotoxic T lymphocyte responses. Journal of Statistical Mechanics: Theory and Experiment, 2013, 2013, P01010.	2.3	38
126	Mathematical analysis of multiscale models for hepatitis C virus dynamics under therapy with direct-acting antiviral agents. Mathematical Biosciences, 2013, 245, 22-30.	1.9	45

#	Article	IF	Citations
127	Kinetics of Coinfection with Influenza A Virus and Streptococcus pneumoniae. PLoS Pathogens, 2013, 9, e1003238.	4.7	184
128	Inferring HIV Escape Rates from Multi-Locus Genotype Data. Frontiers in Immunology, 2013, 4, 252.	4.8	35
129	The hepatitis C virus NS5A inhibitor daclatasvir has a dual mode of action and leads to a new virus half-life estimate. Expert Review of Gastroenterology and Hepatology, 2013, 7, 397-399.	3.0	14
130	Antigen-Stimulated CD4 T Cell Expansion Can Be Limited by Their Grazing of Peptideâ€"MHC Complexes. Journal of Immunology, 2013, 190, 5454-5458.	0.8	12
131	Modeling the Acute and Chronic Phases of Theiler Murine Encephalomyelitis Virus Infection. Journal of Virology, 2013, 87, 4052-4059.	3.4	15
132	Contribution of Follicular Dendritic Cells to Persistent HIV Viremia. Journal of Virology, 2013, 87, 7893-7901.	3.4	29
133	Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. Journal of Clinical Investigation, 2013, 123, 380-93.	8.2	165
134	Analysis of Hepatitis C Virus Decline during Treatment with the Protease Inhibitor Danoprevir Using a Multiscale Model. PLoS Computational Biology, 2013, 9, e1002959.	3.2	83
135	Quantifying the Diversification of Hepatitis C Virus (HCV) during Primary Infection: Estimates of the In Vivo Mutation Rate. PLoS Pathogens, 2012, 8, e1002881.	4.7	139
136	Modeling Within-Host Dynamics of Influenza Virus Infection Including Immune Responses. PLoS Computational Biology, 2012, 8, e1002588.	3.2	223
137	Early Low-Titer Neutralizing Antibodies Impede HIV-1 Replication and Select for Virus Escape. PLoS Pathogens, 2012, 8, e1002721.	4.7	159
138	Elucidation of Hepatitis C Virus Transmission and Early Diversification by Single Genome Sequencing. PLoS Pathogens, 2012, 8, e1002880.	4.7	74
139	Modelling deuterium labelling of lymphocytes with temporal and/or kinetic heterogeneity. Journal of the Royal Society Interface, 2012, 9, 2191-2200.	3.4	22
140	Dominance of the CD4+ T helper cell response during acute resolving hepatitis A virus infection. Journal of Experimental Medicine, 2012, 209, 1481-1492.	8.5	79
141	Combination Antiviral Therapy for Influenza: Predictions From Modeling of Human Infections. Journal of Infectious Diseases, 2012, 205, 1642-1645.	4.0	59
142	Dynamics of CD4+ T Cell Responses against <i>Listeria monocytogenes</i>. Journal of Immunology, 2012, 189, 5250-5256.	0.8	7
143	Precise Determination of Time to Reach Viral Load Set Point After Acute HIV-1 Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 61, 448-454.	2.1	28
144	Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents?. Antiviral Therapy, 2012, 17, 1171-1182.	1.0	58

#	Article	IF	Citations
145	Understanding silibinin's modes of action against HCV using viral kinetic modeling. Journal of Hepatology, 2012, 56, 1019-1024.	3.7	47
146	Impact of immune escape mutations on HIV-1 fitness in the context of the cognate transmitted/founder genome. Retrovirology, 2012, 9, 89.	2.0	50
147	Modeling and Simulation of Aggregation of Membrane Protein LAT with Molecular Variability in the Number of Binding Sites for Cytosolic Grb2-SOS1-Grb2. PLoS ONE, 2012, 7, e28758.	2.5	18
148	Spontaneous Clearance of Viral Infections by Mesoscopic Fluctuations. PLoS ONE, 2012, 7, e38549.	2.5	9
149	Modeling Quasispecies and Drug Resistance in Hepatitis C Patients Treated with a Protease Inhibitor. Bulletin of Mathematical Biology, 2012, 74, 1789-1817.	1.9	38
150	Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128). Hepatology, 2012, 55, 1030-1037.	7.3	51
151	Immediate antiviral therapy appears to restrict resting CD4$^+$ cell HIV-1 infection without accelerating the decay of latent infection. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 9523-9528.	7.1	202
152	Evaluation of Multitype Mathematical Models for CFSE-Labeling Experiment Data. Bulletin of Mathematical Biology, 2012, 74, 300-326.	1.9	28
153	Stochastic Theory of Early Viral Infection: Continuous versus Burst Production of Virions. PLoS Computational Biology, 2011, 7, e1001058.	3.2	114
154	On Identifiability of Nonlinear ODE Models and Applications in Viral Dynamics. SIAM Review, 2011, 53, 3-39.	9.5	412
155	Triple Combination Antiviral Drug (TCAD) Composed of Amantadine, Oseltamivir, and Ribavirin Impedes the Selection of Drug-Resistant Influenza A Virus. PLoS ONE, 2011, 6, e29778.	2.5	48
156	Designing a genome-based HIV incidence assay with high sensitivity and specificity. Aids, 2011, 25, F13-F19.	2.2	39
157	Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and Interleukin-28B. Current Hepatitis Reports, 2011, 10, 214-227.	0.3	52
158	Influenza A virus infection kinetics: quantitative data and models. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2011, 3, 429-445.	6.6	136
159	Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: Implications for treatment duration. Hepatology, 2011, 53, 1801-1808.	7.3	90
160	Silibinin mode(s) of action against hepatitis C virus: A controversy yet to be resolved. Hepatology, 2011, 54, 749-749.	7.3	8
161	Drug Effectiveness Explained: The Mathematics of Antiviral Agents for HIV. Science Translational Medicine, 2011, 3, 91ps30.	12.4	12
162	Dynamic Antibody Specificities and Virion Concentrations in Circulating Immune Complexes in Acute to Chronic HIV-1 Infection. Journal of Virology, 2011, 85, 11196-11207.	3.4	56

#	Article	IF	Citations
163	Fitness Costs and Diversity of the Cytotoxic T Lymphocyte (CTL) Response Determine the Rate of CTL Escape during Acute and Chronic Phases of HIV Infection. Journal of Virology, 2011, 85, 10518-10528.	3.4	141
164	Higher Level of Replication Efficiency of 2009 (H1N1) Pandemic Influenza Virus than Those of Seasonal and Avian Strains: Kinetics from Epithelial Cell Culture and Computational Modeling. Journal of Virology, 2011, 85, 1125-1135.	3.4	64
165	Evolution of Drug-Resistant Viral Populations during Interruption of Antiretroviral Therapy. Journal of Virology, 2011, 85, 6403-6415.	3.4	26
166	Acute hepatitis A virus infection is associated with a limited type I interferon response and persistence of intrahepatic viral RNA. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 11223-11228.	7.1	130
167	Modeling of Influenza-Specific CD8+ T Cells during the Primary Response Indicates that the Spleen Is a Major Source of Effectors. Journal of Immunology, 2011, 187, 4474-4482.	0.8	41
168	Understanding the nature of early HCV RNA blips and the use of mathematical modeling of viral kinetics during IFN-based therapy. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, E302; author reply E303.	7.1	6
169	Effect of 1918 PB1-F2 Expression on Influenza A Virus Infection Kinetics. PLoS Computational Biology, 2011, 7, e1001081.	3.2	67
170	A Signature in HIV-1 Envelope Leader Peptide Associated with Transition from Acute to Chronic Infection Impacts Envelope Processing and Infectivity. PLoS ONE, 2011, 6, e23673.	2.5	54
171	Persistence and emergence of X4 virus in HIV infection. Mathematical Biosciences and Engineering, 2011, 8, 605-626.	1.9	23
172	Quantifying the Early Immune Response and Adaptive Immune Response Kinetics in Mice Infected with Influenza A Virus. Journal of Virology, 2010, 84, 6687-6698.	3.4	185
173	An accurate two-phase approximate solution to an acute viral infection model. Journal of Mathematical Biology, 2010, 60, 711-726.	1.9	75
174	Estimating time since infection in early homogeneous HIV-1 samples using a poisson model. BMC Bioinformatics, 2010, 11, 532.	2.6	83
175	Stochastic Models of Lymphocyte Proliferation and Death. PLoS ONE, 2010, 5, e12775.	2.5	52
176	Estimation of the Initial Viral Growth Rate and Basic Reproductive Number during Acute HIV-1 Infection. Journal of Virology, 2010, 84, 6096-6102.	3.4	203
177	Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus. Science Translational Medicine, 2010, 2, 30ra32.	12.4	327
178	Viral Dynamics during Primary Simian Immunodeficiency Virus Infection: Effect of Time-Dependent Virus Infectivity. Journal of Virology, 2010, 84, 4302-4310.	3.4	48
179	Hepatitis B Virus Kinetics under Antiviral Therapy Sheds Light on Differences in Hepatitis B e Antigen Positive and Negative Infections. Journal of Infectious Diseases, 2010, 202, 1309-1318.	4.0	45
180	CD8+ Lymphocytes Control Viral Replication in SIVmac239-Infected Rhesus Macaques without Decreasing the Lifespan of Productively Infected Cells. PLoS Pathogens, 2010, 6, e1000747.	4.7	146

#	Article	IF	Citations
181	High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathogens, 2010, 6, e1000890.	4.7	263
182	Treatment-Mediated Alterations in HIV Fitness Preserve CD4+ T Cell Counts but Have Minimal Effects on Viral Load. PLoS Computational Biology, 2010, 6, e1001012.	3.2	19
183	Current Estimates for HIV-1 Production Imply Rapid Viral Clearance in Lymphoid Tissues. PLoS Computational Biology, 2010, 6, e1000906.	3.2	75
184	Transmission of Single HIV-1 Genomes and Dynamics of Early Immune Escape Revealed by Ultra-Deep Sequencing. PLoS ONE, 2010, 5, e12303.	2.5	259
185	Treatment of Hepatitis C Virus Infection With Interferon and Small Molecule Direct Antivirals: Viral Kinetics and Modeling. Critical Reviews in Immunology, 2010, 30, 131-148.	0.5	68
186	The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. Journal of Experimental Medicine, 2009, 206, 1253-1272.	8.5	562
187	Simulation and Prediction of the Adaptive Immune Response to Influenza A Virus Infection. Journal of Virology, 2009, 83, 7151-7165.	3.4	163
188	Modeling Latently Infected Cell Activation: Viral and Latent Reservoir Persistence, and Viral Blips in HIV-infected Patients on Potent Therapy. PLoS Computational Biology, 2009, 5, e1000533.	3.2	194
189	Accelerated Immunodeficiency by Anti-CCR5 Treatment in HIV Infection. PLoS Computational Biology, 2009, 5, e1000467.	3.2	9
190	Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. Journal of Experimental Medicine, 2009, 206, 1117-1134.	8.5	295
191	Modeling Subgenomic Hepatitis C Virus RNA Kinetics during Treatment with Alpha Interferon. Journal of Virology, 2009, 83, 6383-6390.	3.4	56
192	Modeling complex decay profiles of hepatitis B virus during antiviral therapy. Hepatology, 2009, 49, 32-38.	7.3	86
193	Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: Similar effectiveness of lamivudine, tenofovir, or combination therapy. Hepatology, 2009, 49, 1113-1121.	7.3	22
194	Hepatitis B virus clearance rate estimates. Hepatology, 2009, 49, 1779-1780.	7.3	10
195	Modeling HIV persistence, the latent reservoir, and viral blips. Journal of Theoretical Biology, 2009, 260, 308-331.	1.7	196
196	Modeling sequence evolution in acute HIV-1 infection. Journal of Theoretical Biology, 2009, 261, 341-360.	1.7	162
197	Interpreting CFSE Obtained Division Histories of B Cells in Vitro with Smith–Martin and Cyton Type Models. Bulletin of Mathematical Biology, 2009, 71, 1649-1670.	1.9	20
198	Scaling aspects of lymphocyte trafficking. Journal of Theoretical Biology, 2009, 257, 9-16.	1.7	28

#	ARTICLE	IF	CITATIONS
199	Agent-based modeling of host–pathogen systems: The successes and challenges. Information Sciences, 2009, 179, 1379-1389.	6.9	174
200	Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. Journal of Experimental Medicine, 2009, 206, 1273-1289.	8.5	684
201	Asymmetric division of activated latently infected cells may explain the decay kinetics of the HIV-1 latent reservoir and intermittent viral blips. Mathematical Biosciences, 2009, 217, 77-87.	1.9	101
202	A Mathematical Model of Hepatitis C Virus Dynamics in Patients With High Baseline Viral Loads or Advanced Liver Disease. Gastroenterology, 2009, 136, 1402-1409.	1.3	56
203	Modeling HCV kinetics under therapy using PK and PD information. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 321-332.	3.3	32
204	Analysis of Hepatitis C Virus Infection Models with Hepatocyte Homeostasis. SIAM Journal on Applied Mathematics, 2009, 69, 999-1023.	1.8	49
205	Mathematical Modeling of HCV Infection and Treatment. Methods in Molecular Biology, 2009, 510, 439-453.	0.9	19
206	Modelling hepatitis C virus kinetics: the relationship between the infected cell loss rate and the final slope of viral decay. Antiviral Therapy, 2009, 14, 459-64.	1.0	16
207	Modelling Hepatitis C virus Kinetics: The Relationship between the Infected Cell Loss rate and the Final Slope of Viral Decay. Antiviral Therapy, 2009, 14, 459-464.	1.0	31
208	Modeling amantadine treatment of influenza A virus in vitro. Journal of Theoretical Biology, 2008, 254, 439-451.	1.7	114
209	Modeling T Cell Proliferation and Death in Vitro Based on Labeling Data: Generalizations of the Smith–Martin Cell Cycle Model. Bulletin of Mathematical Biology, 2008, 70, 21-44.	1.9	29
210	Parameter Identifiability and Estimation of HIV/AIDS Dynamic Models. Bulletin of Mathematical Biology, 2008, 70, 785-799.	1.9	118
211	Modeling and Estimation of Kinetic Parameters and Replicative Fitness of HIV-1 from Flow-Cytometry-Based Growth Competition Experiments. Bulletin of Mathematical Biology, 2008, 70, 1749-1771.	1.9	37
212	Hepatitis C viral kinetics in special populations. Current Hepatitis Reports, 2008, 7, 97-105.	0.3	12
213	Estimating drug efficacy and viral dynamic parameters: HIV and HCV. Statistics in Medicine, 2008, 27, 4647-4657.	1.6	29
214	Backward bifurcations and multiple equilibria in epidemic models with structured immunity. Journal of Theoretical Biology, 2008, 252, 155-165.	1.7	54
215	The effect of early versus delayed challenge after vaccination in controlling SHIV 89.6P infection. Virology, 2008, 381, 75-80.	2.4	2
216	Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia. Journal of Virology, 2008, 82, 12449-12463.	3.4	548

#	Article	IF	Citations
217	The probability of HIV infection in a new host and its reduction with microbicides. Mathematical Biosciences, 2008, 214, 81-86.	1.9	35
218	Recombination increases human immunodeficiency virus fitness, but not necessarily diversity. Journal of General Virology, 2008, 89, 1467-1477.	2.9	57
219	Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 7552-7557.	7.1	1,708
220	Simian Immunodeficiency Virus SIVagm Dynamics in African Green Monkeys. Journal of Virology, 2008, 82, 3713-3724.	3.4	101
221	Dynamics of T- and B-Lymphocyte Turnover in a Natural Host of Simian Immunodeficiency Virus. Journal of Virology, 2008, 82, 1084-1093.	3.4	42
222	Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?. Journal of Antimicrobial Chemotherapy, 2008, 62, 1-4.	3.0	249
223	How Antigen Quantity and Quality Determine T-Cell Decisions in Lymphoid Tissue. Molecular and Cellular Biology, 2008, 28, 4040-4051.	2.3	55
224	Dynamic Correlation between Intrahost HIV-1 Quasispecies Evolution and Disease Progression. PLoS Computational Biology, 2008, 4, e1000240.	3.2	70
225	Short-Lived Infected Cells Support Virus Replication in Sooty Mangabeys Naturally Infected with Simian Immunodeficiency Virus: Implications for AIDS Pathogenesis. Journal of Virology, 2008, 82, 3725-3735.	3.4	73
226	Treatment response in acute/early infection versus advanced AIDS: equivalent first and second phases of HIV RNA decline. Aids, 2008, 22, 957-962.	2.2	22
227	Mathematical Modeling of HIV-1 Infection and Drug Therapy. , 2008, , 87-131.		5
228	A hepatitis C viral kinetic model that allows for time-varying drug effectiveness. Antiviral Therapy, 2008, 13, 919-26.	1.0	15
229	A Hepatitis C Viral Kinetic Model that Allows for Time-Varying Drug Effectiveness. Antiviral Therapy, 2008, 13, 919-926.	1.0	22
230	Complete genetic linkage can subvert natural selection. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 6266-6271.	7.1	79
231	Acute Loss of Intestinal CD4+ T Cells Is Not Predictive of Simian Immunodeficiency Virus Virulence. Journal of Immunology, 2007, 179, 3035-3046.	0.8	253
232	Determination of virus burst size *in vivo* using a single-cycle SIV in rhesus macaques. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 19079-19084.	7.1	132
233	The role of cells refractory to productive infection in acute hepatitis B viral dynamics. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 5050-5055.	7.1	101
234	Characterizing T Cell Movement within Lymph Nodes in the Absence of Antigen. Journal of Immunology, 2007, 178, 5505-5512.	0.8	74

#	Article	IF	Citations
235	Mathematical Modeling of Subgenomic Hepatitis C Virus Replication in Huh-7 Cells. Journal of Virology, 2007, 81, 750-760.	3.4	95
236	HIV–1 Viral Dynamics Studies in the Setting of Clinical Trials—A Window of Opportunity. Journal of Infectious Diseases, 2007, 195, 1087-1088.	4.0	5
237	Transient Viremia, Plasma Viral Load, and Reservoir Replenishment in HIV-Infected Patients on Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 45, 483-493.	2.1	99
238	Polyspecificity of T cell and B cell receptor recognition. Seminars in Immunology, 2007, 19, 216-224.	5.6	194
239	Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin. Journal of Hepatology, 2007, 47, 23-30.	3.7	39
240	Mathematical Analysis of Age–Structured HIV–1 Dynamics with Combination Antiretroviral Therapy. SIAM Journal on Applied Mathematics, 2007, 67, 731-756.	1.8	120
241	Ribavirin: Is It a Mutagen for Hepatitis C Virus?. Gastroenterology, 2007, 132, 2050-2052.	1.3	24
242	Triphasic decline of hepatitis C virus RNA during antiviral therapy. Hepatology, 2007, 46, 16-21.	7.3	115
243	Hepatitis C virus kinetics in chimeric mice during antiviral therapy. Hepatology, 2007, 46, 2048-2049.	7.3	6
244	Modeling the mechanisms of acute hepatitis B virus infection. Journal of Theoretical Biology, 2007, 247, 23-35.	1.7	166
245	Modeling hepatitis C virus dynamics: Liver regeneration and critical drug efficacy. Journal of Theoretical Biology, 2007, 247, 371-381.	1.7	156
246	Modeling within-host HIV-1 dynamics and the evolution of drug resistance: Trade-offs between viral enzyme function and drug susceptibility. Journal of Theoretical Biology, 2007, 247, 804-818.	1.7	107
247	Stochastic model of an influenza epidemic with drug resistance. Journal of Theoretical Biology, 2007, 248, 179-193.	1.7	33
248	Understanding the mechanisms and limitations of immune control of HIV. Immunological Reviews, 2007, 216, 164-175.	6.0	44
249	Determining thymic output quantitatively: using models to interpret experimental T–cell receptor excision circle (TREC) data. Immunological Reviews, 2007, 216, 21-34.	6.0	78
250	Emergence of HIV-1 Drug Resistance During Antiretroviral Treatment. Bulletin of Mathematical Biology, 2007, 69, 2027-2060.	1.9	153
251	Hepatitis C virus RNA kinetics: Drug efficacy and the rate of HCV-infected cells loss. World Journal of Gastroenterology, 2007, 13, 3020.	3.3	5
252	HIV EPIDEMIOLOGY AND THE IMPACT OF NONSTERILIZING VACCINES. , 2007, , .		0

#	ARTICLE	IF	CITATIONS
253	Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B. Antiviral Therapy, 2007, 12, 705-18.	1.0	18
254	Impact of Early Viral Kinetics on T-Cell Reactivity during Antiviral Therapy in Chronic Hepatitis B. Antiviral Therapy, 2007, 12, 705-718.	1.0	35
255	The extrahepatic contribution to HCV plasma viremia. Journal of Hepatology, 2006, 45, 626-627.	3.7	8
256	Pharmacodynamics of Antiretroviral Agents in HIV-1 Infected Patients: Using Viral Dynamic Models that Incorporate Drug Susceptibility and Adherence. Journal of Pharmacokinetics and Pharmacodynamics, 2006, 33, 399-419.	1.8	35
257	Estimating Lymphocyte Division and Death Rates from CFSE Data. Bulletin of Mathematical Biology, 2006, 68, 1011-1031.	1.9	89
258	Pharmacodynamics of PEG-IFN Î± differentiate HIV/HCV coinfected sustained virological responders from nonresponders. Hepatology, 2006, 43, 943-953.	7.3	81
259	Kinetics of hepatitis C virus reinfection after liver transplantation. Liver Transplantation, 2006, 12, 207-216.	2.4	73
260	Influence of Peak Viral Load on the Extent of CD4+ T-Cell Depletion in Simian HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 41, 259-265.	2.1	37
261	Modeling and Estimation of Replication Fitness of Human Immunodeficiency Virus Type 1 In Vitro Experiments by Using a Growth Competition Assay. Journal of Virology, 2006, 80, 2380-2389.	3.4	48
262	Viral and Latent Reservoir Persistence in HIV-1â€"Infected Patients on Therapy. PLoS Computational Biology, 2006, 2, e135.	3.2	81
263	Kinetics of Influenza A Virus Infection in Humans. Journal of Virology, 2006, 80, 7590-7599.	3.4	630
264	NaiÌ̂ve and Memory Cell Turnover as Drivers of CCR5-to-CXCR4 Tropism Switch in Human Immunodeficiency Virus Type 1: Implications for Therapy. Journal of Virology, 2006, 80, 802-809.	3.4	73
265	Viral Decay Dynamics in HIVâ€"Infected Patients Receiving Ritonavirâ€"Boosted Saquinavir and Efavirenz With or Without Enfuvirtide: A Randomized, Controlled Trial (HIVâ€"NAT 012). Journal of Infectious Diseases, 2006, 194, 1319-1322.	4.0	11
266	The Complexity of the Immune System: Scaling Laws. , 2006, , 451-459.		5
267	Dynamic characteristics of HIV-1 reservoirs. Current Opinion in HIV and AIDS, 2006, 1, 152-6.	3.8	4
268	13 Modelling the in vivo growth rate of HIV: implications for vaccination. Studies in Multidisciplinarity, 2005, , 231-246.	0.0	6
269	Modeling Long-Term HIV Dynamics and Antiretroviral Response. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 39, 272-283.	2.1	75
270	Optimization of Influenza Vaccine Selection. Operations Research, 2005, 53, 456-476.	1.9	50

#	Article	IF	Citations
271	Duration of an intermittent episode of viremia. Bulletin of Mathematical Biology, 2005, 67, 885-900.	1.9	12
272	Estimating division and death rates from CFSE data. Journal of Computational and Applied Mathematics, 2005, 184, 140-164.	2.0	47
273	Impact of thymectomy on the peripheral T cell pool in rhesus macaques before and after infection with simian immunodeficiency virus. European Journal of Immunology, 2005, 35, 46-55.	2.9	40
274	The effects of thymic selection on the range of Tâ€„cell cross-reactivity. European Journal of Immunology, 2005, 35, 3452-3459.	2.9	27
275	New kinetic models for the hepatitis C virus. Hepatology, 2005, 42, 749-754.	7.3	137
276	Opportunistic infection as a cause of transient viremia in chronically infected HIV patients under treatment with HAART. Bulletin of Mathematical Biology, 2005, 67, 1227-1251.	1.9	65
277	Analysis of Human Immunodeficiency Virus Cytopathicity by Using a New Method for Quantitating Viral Dynamics in Cell Culture. Journal of Virology, 2005, 79, 4025-4032.	3.4	18
278	High-Potency Human Immunodeficiency Virus Vaccination Leads to Delayed and Reduced CD8 + T-Cell Expansion but Improved Virus Control. Journal of Virology, 2005, 79, 10059-10062.	3.4	28
279	HIV dynamics with multiple infections of target cells. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 8198-8203.	7.1	94
280	Hepatitis C Virus Genotype 1a NS5A Pretreatment Sequence Variation and Viral Kinetics in African American and White Patients. Journal of Infectious Diseases, 2005, 192, 1078-1087.	4.0	31
281	Human Immunodeficiency Virus: Quasi-Species and Drug Resistance. Multiscale Modeling and Simulation, 2005, 3, 300-311.	1.6	13
282	Mutagenic effects of ribavirin in vivo. Journal of Hepatology, 2005, 43, 553-555.	3.7	13
283	Mathematical modeling of primary hepatitis C infection: Noncytolytic clearance and early blockage of virion production. Gastroenterology, 2005, 128, 1056-1066.	1.3	109
284	INFLUENCE OF DRUG PHARMACOKINETICS ON HIV PATHOGENESIS AND THERAPY. , 2005, , 287-311.		3
285	Effects of Antibody on Viral Kinetics in Simian/Human Immunodeficiency Virus Infection: Implications for Vaccination. Journal of Virology, 2004, 78, 5520-5522.	3.4	23
286	Hepatitis B Virus Kinetics and Mathematical Modeling. Seminars in Liver Disease, 2004, 24, 11-16.	3.6	37
287	Multiplicity of Human Immunodeficiency Virus Infections in Lymphoid Tissue. Journal of Virology, 2004, 78, 8942-8945.	3.4	79
288	Dynamics of Intermittent Viremia during Highly Active Antiretroviral Therapy in Patients Who Initiate Therapy during Chronic versus Acute and Early Human Immunodeficiency Virus Type 1 Infection. Journal of Virology, 2004, 78, 10566-10573.	3.4	68

#	Article	IF	Citations
289	Predicting the Impact of a Nonsterilizing Vaccine against Human Immunodeficiency Virus. Journal of Virology, 2004, 78, 11340-11351.	3.4	61
290	Intensification of Antiretroviral Therapy Accelerates the Decay of the HIV-1 Latent Reservoir and Decreases, But Does Not Eliminate, Ongoing Virus Replication. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 35, 33-37.	2.1	103
291	Virus Dynamics and Immune Responses During Treatment in Patients Coinfected With Hepatitis C and HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 35, 103-113.	2.1	26
292	Kinetics of Virus-Specific CD8 + T Cells and the Control of Human Immunodeficiency Virus Infection. Journal of Virology, 2004, 78, 10096-10103.	3.4	105
293	Modelling the impact of antigen kinetics on Tâ€cell activation and response. Immunology and Cell Biology, 2004, 82, 55-61.	2.3	10
294	Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature, 2004, 432, 922-924.	27.8	344
295	The Analysis of HIV Dynamics Using Mathematical Models. , 2004, , 905-912.		5
296	Some Scaling Principles for the Immune System. Immunology and Cell Biology, 2004, 82, 127-131.	2.3	56
297	Complex patterns of viral load decay under antiretroviral therapy: influence of pharmacokinetics and intracellular delay. Journal of Theoretical Biology, 2004, 226, 95-109.	1.7	163
298	A stochastic model of cytotoxic T cell responses. Journal of Theoretical Biology, 2004, 228, 227-240.	1.7	91
299	Optimizing within-host viral fitness: infected cell lifespan and virion production rate. Journal of Theoretical Biology, 2004, 229, 281-288.	1.7	89
300	The life span of ganglionic glia in murine sensory ganglia estimated by uptake of bromodeoxyuridine. Experimental Neurology, 2004, 186, 99-103.	4.1	14
301	Modeling the long-term control of viremia in HIV-1 infected patients treated with antiretroviral therapy. Mathematical Biosciences, 2004, 188, 47-62.	1.9	48
302	An Age-Structured Model of HIV Infection that Allows for Variations in the Production Rate of Viral Particles and the Death Rate of Productively Infected Cells. Mathematical Biosciences and Engineering, 2004, 1, 267-288.	1.9	120
303	Estimates of intracellular delay and average drug efficacy from viral load data of HIV-infected individuals under antiretroviral therapy. Antiviral Therapy, 2004, 9, 237-46.	1.0	31
304	Estimates of Intracellular Delay and Average Drug Efficacy from Viral Load Data of HIV-Infected Individuals under Antiretroviral Therapy. Antiviral Therapy, 2004, 9, 237-246.	1.0	79
305	Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology, 2003, 37, 1343-1350.	7.3	175
306	Liver transplantation with hepatitis C virus-infected graft: Interaction between donor and recipient viral strains. Hepatology, 2003, 38, 25-33.	7.3	32

#	ARTICLE	IF	CITATIONS
307	Dynamics of alanine aminotransferase during hepatitis C virus treatment. Hepatology, 2003, 38, 509-517.	7.3	54
308	The complexity of complexes in signal transduction. Biotechnology and Bioengineering, 2003, 84, 783-794.	3.3	176
309	A sheep in wolf's clothing. Hepatology, 2003, 38, 1588-1589.	7.3	0
310	The Distribution of Viral Blips Observed in HIV-1 Infected Patients Treated with Combination Antiretroviral Therapy. Bulletin of Mathematical Biology, 2003, 65, 263-277.	1.9	22
311	Optimal viral production. Bulletin of Mathematical Biology, 2003, 65, 1003-1023.	1.9	23
312	Mathematical modeling of viral kinetics:. Clinics in Liver Disease, 2003, 7, 163-178.	2.1	46
313	A Novel Antiviral Intervention Results in More Accurate Assessment of Human Immunodeficiency Virus Type 1 Replication Dynamics and T-Cell Decay In Vivo. Journal of Virology, 2003, 77, 5037-5038.	3.4	356
314	Turnover Rates of B Cells, T Cells, and NK Cells in Simian Immunodeficiency Virus-Infected and Uninfected Rhesus Macaques. Journal of Immunology, 2003, 170, 2479-2487.	0.8	115
315	Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Dynamics during HCV Treatment in HCV/HIV Coinfection. Journal of Infectious Diseases, 2003, 188, 1498-1507.	4.0	99
316	Determining the Relative Efficacy of Highly Active Antiretroviral Therapy. Journal of Infectious Diseases, 2003, 187, 896-900.	4.0	85
317	In a Subset of Subjects on Highly Active Antiretroviral Therapy, Human Immunodeficiency Virus Type 1 RNA in Plasma Decays from 50 to <5 Copies per Milliliter, with a Half-Life of 6 Months. Journal of Virology, 2003, 77, 2271-2275.	3.4	59
318	Estimating average cellular turnover from 5–bromo–2'–deoxyuridine (BrdU) measurements. Proceedings of the Royal Society B: Biological Sciences, 2003, 270, 849-858.	2.6	36
319	Viral Blip Dynamics during Highly Active Antiretroviral Therapy. Journal of Virology, 2003, 77, 12165-12172.	3.4	76
320	Different Dynamics of CD4+ and CD8+ T Cell Responses During and After Acute Lymphocytic Choriomeningitis Virus Infection. Journal of Immunology, 2003, 171, 3928-3935.	0.8	231
321	Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals. Aids, 2003, 17, 1151-1156.	2.2	77
322	Modeling Viral and Drug Kinetics: Hepatitis C Virus Treatment with Pegylated Interferon Alfa-2b. Seminars in Liver Disease, 2003, 23, 013-018.	3.6	47
323	Nonlinear partial differential equations and applications: In vivo dynamics of T cell activation, proliferation, and death in HIV-1 infection: Why are CD4+ but not CD8+ T cells depleted?. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 15572-15577.	7.1	177
324	Dynamics of T Cells and TCR Excision Circles Differ After Treatment of Acute and Chronic HIV Infection. Journal of Immunology, 2002, 169, 4657-4666.	0.8	49

#	ARTICLE	IF	CITATIONS
325	Discontinuation of Antiretroviral Therapy Commenced Early during the Course of Human Immunodeficiency Virus Type 1 Infection, with or without Adjunctive Vaccination. Journal of Infectious Diseases, 2002, 186, 634-643.	4.0	129
326	Modeling the Effects of Vaccination on Chronically Infected HIV-Positive Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 31, 369-377.	2.1	20
327	Effect of target cell availability on HIV-1 production in vitro. Aids, 2002, 16, 341-345.	2.2	9
328	Evolution of hepatitis C viral quasispecies after liver transplantation. Gastroenterology, 2002, 123, 1485-1493.	1.3	56
329	Drug resistance and influenza pandemics. Lancet, The, 2002, 359, 1862-1863.	13.7	16
330	Retention of antigen on follicular dendritic cells and B lymphocytes through complement-mediated multivalent ligand–receptor interactions: theory and application to HIV treatment. Mathematical Biosciences, 2002, 176, 185-202.	1.9	26
331	Mathematical analysis of delay differential equation models of HIV-1 infection. Mathematical Biosciences, 2002, 179, 73-94.	1.9	398
332	Early hepatitis C viral kinetics correlate with long-term outcome in patients receiving high dose induction followed by combination interferon and ribavirin therapy. Journal of Hepatology, 2002, 37, 124-130.	3.7	36
333	Hepatitis B virus viral dynamics: effects of drug dose and baseline alanine aminotransferase. Journal of Hepatology, 2002, 37, 277-279.	3.7	5
334	Bayesian Analysis of a Population HIV Dynamic Model. Lecture Notes in Statistics, 2002, , 223-237.	0.2	25
335	HIV-1 Infection and Low Steady State Viral Loads. Bulletin of Mathematical Biology, 2002, 64, 29-64.	1.9	307
336	Modeling Deuterated Glucose Labeling of T-lymphocytes. Bulletin of Mathematical Biology, 2002, 64, 385-405.	1.9	31
337	Modelling viral and immune system dynamics. Nature Reviews Immunology, 2002, 2, 28-36.	22.7	832
338	Dynamics of hepatitis B virus infection. Microbes and Infection, 2002, 4, 829-835.	1.9	119
339	Modeling the effects of updating the influenza vaccine on the efficacy of repeated vaccination. International Congress Series, 2001, 1219, 655-660.	0.2	5
340	Effect of Drug Efficacy and the Eclipse Phase of the Viral Life Cycle on Estimates of HIV Viral Dynamic Parameters. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 26, 405-412.	2.1	14
341	Resource Competition Determines Selection of B Cell Repertoires. Journal of Theoretical Biology, 2001, 212, 333-343.	1.7	28
342	Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model. Hepatology, 2001, 33, 419-423.	7.3	70

#	ARTICLE	IF	CITATIONS
343	Analysis of hepatitis B viral load decline under potent therapy: Complex decay profiles observed. Hepatology, 2001, 34, 1012-1020.	7.3	201
344	Recruitment Times, Proliferation, and Apoptosis Rates during the CD8 + T-Cell Response to Lymphocytic Choriomeningitis Virus. Journal of Virology, 2001, 75, 10663-10669.	3.4	175
345	Effect of Drug Efficacy and the Eclipse Phase of the Viral Life Cycle on Estimates of HIV Viral Dynamic Parameters. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 26, 405-412.	2.1	59
346	Increased Turnover of T Lymphocytes in HIV-1 Infection and Its Reduction by Antiretroviral Therapy. Journal of Experimental Medicine, 2001, 194, 1277-1288.	8.5	329
347	Persistence of Infectious HIV on Follicular Dendritic Cells. Journal of Immunology, 2001, 166, 690-696.	0.8	175
348	Kinetics of Acute Hepatitis B Virus Infection in Humans. Journal of Experimental Medicine, 2001, 193, 847-854.	8.5	178
349	Short-Term Measures of Relative Efficacy Predict Longer-Term Reductions in Human Immunodeficiency Virus Type 1 RNA Levels following Nelfinavir Monotherapy. Antimicrobial Agents and Chemotherapy, 2001, 45, 1438-1443.	3.2	24
350	Dynamics of One-pass Germinal Center Models: Implications for Affinity Maturation. Bulletin of Mathematical Biology, 2000, 62, 121-153.	1.9	35
351	Modeling Plasma Virus Concentration during Primary HIV Infection. Journal of Theoretical Biology, 2000, 203, 285-301.	1.7	416
352	The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nature Medicine, 2000, 6, 82-85.	30.7	435
353	Random binding of dimers to chains. Journal of Mathematical Biology, 2000, 40, 278-294.	1.9	1
354	Effects of in Vivo Cd8+ T Cell Depletion on Virus Replication in Rhesus Macaques Immunized with a Live, Attenuated Simian Immunodeficiency Virus Vaccine. Journal of Experimental Medicine, 2000, 191, 1921-1932.	8.5	147
355	Deriving Quantitative Constraints on T Cell Selection from Data on the Mature T Cell Repertoire. Journal of Immunology, 2000, 164, 121-128.	0.8	29
356	Quantification of Cell Turnover Kinetics Using 5-Bromo-2′-deoxyuridine1. Journal of Immunology, 2000, 164, 5049-5054.	0.8	95
357	A model of HIV-1 pathogenesis that includes an intracellular delay. Mathematical Biosciences, 2000, 163, 201-215.	1.9	326
358	Different turnover rate of hepatitis C virus clearance by different treatment regimen using interferon-beta. Journal of Hepatology, 2000, 33, 313-322.	3.7	26
359	Influence of follicular dendritic cells on HIV dynamics. Philosophical Transactions of the Royal Society B: Biological Sciences, 2000, 355, 1051-1058.	4.0	25
360	Dramatic Rise in Plasma Viremia after CD8+ T Cell Depletion in Simian Immunodeficiency Virus–infected Macaques. Journal of Experimental Medicine, 1999, 189, 991-998.	8.5	1,311

#	Article	IF	Citations
361	Variable efficacy of repeated annual influenza vaccination. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 14001-14006.	7.1	347
362	A Quantitative Theory of Affinity-driven T Cell Repertoire Selection. Journal of Theoretical Biology, 1999, 200, 389-403.	1.7	42
363	Th1/Th2 Differentiation and Cross-regulation. Bulletin of Mathematical Biology, 1999, 61, 403-436.	1.9	49
364	Some design principles for immune system recognition. Complexity, 1999, 4, 29-37.	1.6	10
365	Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet, The, 1999, 354, 1782-1785.	13.7	458
366	Mathematical Analysis of HIV-1 Dynamics in Vivo. SIAM Review, 1999, 41, 3-44.	9.5	1,269
367	Quantifying Residual HIV-1 Replication in Patients Receiving Combination Antiretroviral Therapy. New England Journal of Medicine, 1999, 340, 1605-1613.	27.0	782
368	Persistence of HIV-1 Transcription in Peripheral-Blood Mononuclear Cells in Patients Receiving Potent Antiretroviral Therapy. New England Journal of Medicine, 1999, 340, 1614-1622.	27.0	579
369	Quantifying Aggregation of IgE-FcÏµRI by Multivalent Antigen. Biophysical Journal, 1999, 76, 2421-2431.	0.5	35
370	Steric Effects on Multivalent Ligand-Receptor Binding: Exclusion of Ligand Sites by Bound Cell Surface Receptors. Biophysical Journal, 1999, 76, 3031-3043.	0.5	124
371	Viral kinetics and mathematical models. American Journal of Medicine, 1999, 107, 49-52.	1.5	24
372	Improved estimates for H1V-1 clearance rate and intracellular delay. Aids, 1999, 13, 1415.	2.2	82
373	Rapid Clearance of Simian Immunodeficiency Virus Particles from Plasma of Rhesus Macaques. Journal of Virology, 1999, 73, 855-860.	3.4	84
374	Evolution of Envelope Sequences of Human Immunodeficiency Virus Type 1 in Cellular Reservoirs in the Setting of Potent Antiviral Therapy. Journal of Virology, 1999, 73, 9404-9412.	3.4	187
375	Using Lazy Evaluation to Simulate Realistic-size Repertoires in Models of the Immune System. Bulletin of Mathematical Biology, 1998, 60, 647-658.	1.9	18
376	Target Cell Limited and Immune Control Models of HIV Infection: A Comparison. Journal of Theoretical Biology, 1998, 190, 201-214.	1.7	296
377	Mathematical Analysis of Antiretroviral Therapy Aimed at HIV-1 Eradication or Maintenance of Low Viral Loads. Journal of Theoretical Biology, 1998, 192, 81-98.	1.7	108
378	Influence of delayed viral production on viral dynamics in HIV-1 infected patients. Mathematical Biosciences, 1998, 152, 143-163.	1.9	243

#	ARTICLE	IF	CITATIONS
379	Turnover of CD4+ and CD8+ T Lymphocytes in HIV-1 Infection as Measured by Ki-67 Antigen. Journal of Experimental Medicine, 1998, 187, 1295-1303.	8.5	310
380	Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy. Science, 1998, 282, 103-107.	12.6	1,875
381	Rapid Turnover of T Lymphocytes in SIV-Infected Rhesus Macaques. Science, 1998, 279, 1223-1227.	12.6	343
382	Drug concentration heterogeneity facilitates the evolution of drug resistance. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 11514-11519.	7.1	240
383	Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine. Aids, 1998, 12, 1567-1570.	2.2	41
384	Rate of HIV-1 decline following antiretroviral therapy is related to viral load at baseline and drug regimen. Aids, 1998, 12, 1483-1490.	2.2	79
385	Measurement of receptor cross-linking at the cell surface via multiparameter flow cytometry. , 1998, , .		1
386	Role of the Thymus in Pediatric HIV-1 Infection. Journal of Acquired Immune Deficiency Syndromes, 1998, 18, 95-109.	0.3	36
387	MHC-Linked Syngeneic Developmental Preference in Thymic Lobes Colonized with Bone Marrow Cells: A Mathematical model. Autoimmunity, 1998, 5, 303-318.	0.6	8
388	Mathematical and Computational Challenges in Population Biology and Ecosystems Science. Science, 1997, 275, 334-343.	12.6	351
389	Immunology for physicists. Reviews of Modern Physics, 1997, 69, 1219-1268.	45.6	490
390	Immunons revisited: Binding of multivalent antigens to B cells. Molecular Immunology, 1997, 34, 63-74.	2.2	50
391	Decay characteristics of HIV-1-infected compartments during combination therapy. Nature, 1997, 387, 188-191.	27.8	1,722
392	Regulatory feedback pathways in the thymus. Trends in Immunology, 1997, 18, 581-585.	7.5	37
393	Somatic Evolution in the Immune System: The Need for Germinal Centers for Efficient Affinity Maturation. Journal of Theoretical Biology, 1997, 186, 159-171.	1.7	16
394	Deriving Shape Space Parameters from Immunological Data. Journal of Theoretical Biology, 1997, 189, 141-150.	1.7	66
395	Blind T-Cell Homeostasis and the CD4/CD8 Ratio in the Thymus and Peripheral Blood. Journal of Acquired Immune Deficiency Syndromes, 1997, 14, 387-398.	0.3	26
396	Equilibrium binding of multivalent ligands to cells: Effects of cell and receptor density. Mathematical Biosciences, 1996, 135, 147-185.	1.9	34

#	Article	IF	Citations
397	Feedback regulation of T cell development: manifestations in aging. Mechanisms of Ageing and Development, 1996, 91, 195-210.	4.6	30
398	Quantitative Image Analysis of HIV-1 Infection in Lymphoid Tissue. Science, 1996, 274, 985-989.	12.6	583
399	HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time. Science, 1996, 271, 1582-1586.	12.6	3,161
400	A new bell-shaped function for idiotypic interactions based on cross-linking. Bulletin of Mathematical Biology, 1996, 58, 285-312.	1.9	9
401	Feedback Regulation of T Cell Development in the Thymus. Journal of Theoretical Biology, 1996, 181, 157-167.	1.7	32
402	Exploring the Mechanisms of Primary Antibody Responses to T Cell-Dependent Antigens. Journal of Theoretical Biology, 1996, 181, 215-235.	1.7	39
403	Size and Connectivity of the Idiotypic Network Are Independent of the Discreteness of the Affinity Distribution. Journal of Theoretical Biology, 1996, 183, 409-416.	1.7	22
404	A new bell-shaped function for idiotypic interactions based on cross-linking. Bulletin of Mathematical Biology, 1996, 58, 285-312.	1.9	4
405	Base Pairing Probabilities in a Complete HIV-1 RNA. Journal of Computational Biology, 1996, 3, 253-274.	1.6	28
406	Author??s Reply. Journal of Acquired Immune Deficiency Syndromes, 1995, 10, 391.	0.3	0
407	Modeling positive and negative selection and differentiation processes in the thymus. Journal of Theoretical Biology, 1995, 175, 103-126.	1.7	45
408	Towards a general function describing t cell proliferation. Journal of Theoretical Biology, 1995, 175, 567-576.	1.7	145
409	Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature, 1995, 373, 123-126.	27.8	4,277
410	Cyclosporin A. Nature, 1995, 375, 198-198.	27.8	13
411	Lymphocyte memory and affinity selection. Journal of Theoretical Biology, 1995, 173, 241-262.	1.7	10
412	Modeling defective interfering virus therapy for AIDS: Conditions for DIV survival. Mathematical Biosciences, 1995, 125, 127-153.	1.9	26
413	Immune networks modeled by replicator equations. Journal of Mathematical Biology, 1994, 33, 111-137.	1.9	15
414	T Cell Repertoires and Competitive Exclusion. Journal of Theoretical Biology, 1994, 169, 375-390.	1.7	116

#	Article	IF	Citations
415	Th1/Th2 Cross Regulation. Journal of Theoretical Biology, 1994, 170, 25-56.	1.7	69
416	Modeling HIV Infection of CD4+ T-cell Subpopulations. Journal of Theoretical Biology, 1994, 170, 367-391.	1.7	114
417	Nonlinear dynamics of immunogenic tumors: Parameter estimation and global bifurcation analysis. Bulletin of Mathematical Biology, 1994, 56, 295-321.	1.9	578
418	Immune Network Behavior: Oscillations, Chaos and Stationary States. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 1994, 27, 169-171.	0.4	0
419	Cell Protrusions. Lecture Notes in Biomathematics, 1994, , 53-78.	0.3	8
420	Immune Networks and Immune Responses. Lecture Notes in Biomathematics, 1994, , 159-172.	0.3	1
421	Modeling T Cell-Antigen Presenting Cell Interactions. Journal of Theoretical Biology, 1993, 160, 311-342.	1.7	30
422	Somatic Hypermutation in B Cells: An Optimal Control Treatment. Journal of Theoretical Biology, 1993, 164, 37-64.	1.7	141
423	Cyclic re-entry of germinal center B cells and the efficiency of affinity maturation. Trends in Immunology, 1993, 14, 412-415.	7.5	258
424	Immune network behaviorâ€"I. From stationary states to limit cycle oscilations. Bulletin of Mathematical Biology, 1993, 55, 745-780.	1.9	48
425	Immune network behaviorâ€"II. From oscillations to chaos and stationary states. Bulletin of Mathematical Biology, 1993, 55, 781-816.	1.9	29
426	A Cayley tree immune network model with antibody dynamics. Bulletin of Mathematical Biology, 1993, 55, 1091-1131.	1.9	24
427	Dynamics of HIV infection of CD4+ T cells. Mathematical Biosciences, 1993, 114, 81-125.	1.9	776
428	Quantitative Model of ColE1 Plasmid Copy Number Control. Journal of Molecular Biology, 1993, 229, 860-872.	4.2	46
429	Using Genetic Algorithms to Explore Pattern Recognition in the Immune System. Evolutionary Computation, 1993, 1, 191-211.	3.0	209
430	Predicting the size of the T-cell receptor and antibody combining region from consideration of efficient self-nonself discrimination.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 1691-1695.	7.1	127
431	Searching for Diverse, Cooperative Populations with Genetic Algorithms. Evolutionary Computation, 1993, 1, 127-149.	3.0	182
432	Population Diversity in an Immune System Model: Implications for Genetic Search. Foundations of Genetic Algorithms, 1993, , 153-165.	0.6	24

#	Article	IF	Citations
433	Evidence for p55–p75 heterodimers in the absence of IL-2 from Scatchard plot analysis. International Immunology, 1992, 4, 23-32.	4.0	26
434	Pattern formation in one- and two-dimensional shape-space models of the immune system. Journal of Theoretical Biology, 1992, 155, 295-333.	1.7	96
435	Plasmid copy number control: a case study of the quasi-steady-state assumption. Journal of Theoretical Biology, 1992, 158, 481-494.	1.7	7
436	Modeling immune reactivity in secondary lymphoid organs. Bulletin of Mathematical Biology, 1992, 54, 649-672.	1.9	13
437	Probability of Self-Nonself Discrimination. , 1992, , 63-70.		7
438	Interaction of Interleukin-2 with its Cell Surface Receptors: Interpretation of Equilibrium Binding Experiments via Scatchard Plots. , 1992, , 117-148.		1
439	Evolutionary Walks on Rugged Landscapes. SIAM Journal on Applied Mathematics, 1991, 51, 799-827.	1.8	65
440	Size and connectivity as emergent properties of a developing immune network. Journal of Theoretical Biology, 1991, 149, 381-424.	1.7	128
441	Exploiting the diversity of time scales in the immune system: A B-cell antibody model. Journal of Statistical Physics, 1991, 63, 1113-1131.	1.2	19
442	Localized memories in idiotypic networks. Journal of Theoretical Biology, 1990, 146, 483-499.	1.7	86
443	A Paradoxical Instability Caused by Relatively Short-Range Inhibition. SIAM Journal on Applied Mathematics, 1990, 50, 91-107.	1.8	12
444	Genetic algorithms and the immune system. , 1990, , 319-325.		34
445	Shape space: an approach to the evaluation of cross-reactivity effects, stability and controllability in the immune system. Immunology Letters, 1989, 22, 91-99.	2.5	25
446	Vesicle formation in the Golgi apparatus. Journal of Theoretical Biology, 1989, 141, 463-504.	1.7	16
447	Immune Network Theory. Immunological Reviews, 1989, 110, 5-36.	6.0	317
448	Modeling the Interaction of the Immune System with HIV. Lecture Notes in Biomathematics, 1989, , 350-370.	0.3	92
449	Kinetics of complementary RNA-RNA interaction involved in plasmid ColE1 copy number control. Journal of Molecular Biology, 1989, 208, 245-255.	4.2	21
450	Protein evolution on rugged landscapes.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 6191-6195.	7.1	132

#	ARTICLE	IF	CITATIONS
451	Shape space analysis of immune networks. , 1989, , 273-283.		16
452	Immune networks: A topological view. , 1989, , 261-272.		1
453	The Physics of Cell Motility. Journal of Cell Science, 1987, 1987, 35-54.	2.0	172
454	Adaptive Dynamic Networks as Models for the Immune System and Autocatalytic Sets. Annals of the New York Academy of Sciences, 1987, 504, 118-131.	3.8	44
455	Kinetic Analysis of Adsorption Processes. SIAM Journal on Applied Mathematics, 1987, 47, 1306-1319.	1.8	11
456	A note on stochastic models for bacterial adhesion. Journal of Theoretical Biology, 1987, 126, 247-249.	1.7	2
457	The immune system, adaptation, and machine learning. Physica D: Nonlinear Phenomena, 1986, 22, 187-204.	2.8	948
458	A moving boundary model of acrosomal elongation. Journal of Mathematical Biology, 1986, 23, 361-379.	1.9	22
459	Cell spreading and motility: A model lamellipod. Journal of Mathematical Biology, 1985, 21, 383-388.	1.9	22
460	Some stochastic models in immunology. Acta Applicandae Mathematicae, 1985, 4, 157-200.	1.0	3
461	The equilibrium aggregate size distribution of self-associating trivalent molecules. Macromolecules, 1985, 18, 1588-1597.	4.8	5
462	Branching Processes Applied to Cell Surface Aggregation Phenomena. Lecture Notes in Biomathematics, 1985, , .	0.3	17
463	KINETICS OF RED BLOOD CELL AGGREGATION: AN EXAMPLE OF GEOMETRIC POLYMERIZATION. , 1984, , 137-144.		13
464	A method for determining whether the descending limb of a biphasic histamine release curve reflects insufficient cross-linking. Molecular Immunology, 1982, 19, 13-20.	2.2	5
465	Statistical mechanics of red blood cell aggregation: The distribution of rouleaux in thermal equilibrium. Journal of Statistical Physics, 1982, 29, 813-848.	1.2	24
466	A mechanical model for elongation of the acrosomal process in Thyone sperm. Journal of Mathematical Biology, 1982, 15, 259-265.	1.9	31
467	Aggregation of cell surface receptors by multivalent ligands. Journal of Mathematical Biology, 1982, 14, 365-370.	1.9	14
468	Receptor clustering on a cell surface. III. theory of receptor cross-linking by multivalent ligands: description by ligand states. Mathematical Biosciences, 1981, 53, 1-39.	1.9	72

#	Article	IF	Citations
469	Configurations of a polymeric antigen adsorbed to a B-cell membrane. Journal of Theoretical Biology, 1981, 88, 533-568.	1.7	13
470	Optimal strategies in immunology III. The IgM-IgG switch. Journal of Mathematical Biology, 1980, 10, 209-256.	1.9	37
471	Receptor clustering on a cell surface. I. theory of receptor cross-linking by ligands bearing two chemically identical functional groups. Mathematical Biosciences, 1980, 48, 71-110.	1.9	147
472	Receptor clustering on a cell surface. II. theory of receptor cross-linking by ligands bearing two chemically distinct functional groups. Mathematical Biosciences, 1980, 49, 87-110.	1.9	29
473	Tumors and the immune system: the effects of a tumor growth modulator. Mathematical Biosciences, 1980, 50, 25-58.	1.9	26
474	Theoretical studies of clonal selection: Minimal antibody repertoire size and reliability of self-non-self discrimination. Journal of Theoretical Biology, 1979, 81, 645-670.	1.7	583
475	A calculation of the number of IgG molecules required per cell to fix complement. Journal of Theoretical Biology, 1979, 79, 317-332.	1.7	10
476	The effect of indicator layer thickness on the interpretation of hemolytic plaque results. Molecular Immunology, 1979, 16, 395-400.	2.2	0
477	Optimal strategies in immunology. Journal of Mathematical Biology, 1978, 5, 213-256.	1.9	46
478	A singular perturbation approach to diffusion reaction equations containing a point source, with application to the hemolytic plaque assay. Journal of Mathematical Biology, 1978, 6, 75-85.	1.9	10
479	Spatial distribution of surface immunoglobulin on B lymphocytes. Experimental Cell Research, 1978, 112, 309-321.	2.6	25
480	The IgM-IgG switch looked at from a control theoretic viewpoint. , 1978, , 431-440.		4
481	Applications of Optimal Control Theory to Immunology. Lecture Notes in Economics and Mathematical Systems, 1978, , 272-287.	0.3	7
482	The arbitrary dynamic behavior of open chemical reaction systems. Journal of Chemical Physics, 1977, 66, 4390-4394.	3.0	9
483	The hemolytic plaque assay: theory for finite layers. Biophysical Chemistry, 1977, 7, 15-32.	2.8	5
484	Mathematical models for the evolution of multigene families by unequal crossing over. Nature, 1977, 265, 304-310.	27.8	67
485	Optimal strategies in immunology. Journal of Mathematical Biology, 1976, 3, 325-367.	1.9	75
486	Description of electrical networks using bond graphs. International Journal of Circuit Theory and Applications, 1976, 4, 107-123.	2.0	13

#	Article	IF	Citations
487	On the application of network theory to nonisothermal systems. International Journal of Circuit Theory and Applications, 1976, 4, 299-305.	2.0	8
488	Bond graphs and linear graphs. Journal of the Franklin Institute, 1976, 302, 159-185.	3.4	24
489	The electrophoretic hemolytic plaque assay - theory. Biophysical Chemistry, 1976, 4, 349-362.	2.8	7
490	The kinetics of aggregation phenomena I. Minimal models for patch formation on lymphocyte membranes. Journal of Theoretical Biology, 1976, 62, 159-210.	1.7	52
491	Remarks on conservation of mass in open chemical reaction systems. Journal of Theoretical Biology, 1976, 63, 233-237.	1.7	3
492	Restrictions on chemical kinetic models. Journal of Chemical Physics, 1976, 65, 284-292.	3.0	17
493	A systematic and graphical method for generating the kinetic equations governing the growth of aggregates. Journal of Chemical Physics, 1975, 62, 4053-4061.	3.0	7
494	Chemical reaction dynamics. Archive for Rational Mechanics and Analysis, 1974, 55, 230-274.	2.4	90
495	Chemical reaction dynamics part II: Reaction networks. Archive for Rational Mechanics and Analysis, 1974, 57, 31-98.	2.4	55
496	Network thermodynamics: dynamic modelling of biophysical systems. Quarterly Reviews of Biophysics, 1973, 6, 1-134.	5.7	336
497	Systems, Circuits and Thermodynamics. Israel Journal of Chemistry, 1973, 11, 445-478.	2.3	25
498	The relationship between the thermodynamic and kinetic reaction diffusion parameters. Chemical Engineering Science, 1972, 27, 1190-1192.	3.8	6
499	Network Thermodynamics. Nature, 1971, 234, 393-399.	27.8	217
500	Accumulated Mutations Cause Significant Fitness Losses and are Associated with Decreased Viral Loads During Early HIV-1 Infection. SSRN Electronic Journal, 0, , .	0.4	0
501	Computational Models of B cell and T cell Receptors. , 0, , 65-81.		3